Sara Prickett PhD

Sara Prickett has over 25 years’ research experience in cellular immunology in the fields of Infection and Immunity and Allergy, including 10 years within Biotech. She is a co-founder and Chief Scientific Officer of Aravax, where she has overseen the transition of Aravax’s peanut allergy peptide therapeutic from basic research into commercial development, through to Phase 2 trials. Prior to Aravax, Dr Prickett held senior research posts at Alfred Health and Monash University, where she played a major role in the research underpinning the peanut allergy therapy being developed by Aravax. Dr Prickett received her Bachelor of Science from Sheffield University and her PhD from Imperial College, London.